Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Nuo Therapeutics Inc
OTC:AURX

Watchlist Manager
Nuo Therapeutics Inc Logo
Nuo Therapeutics Inc
OTC:AURX
Watchlist
Price: 1.6 USD Market Closed
Market Cap: $77.2m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

AURX Price Targets Summary
Nuo Therapeutics Inc

Wall Street analysts forecast AURX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AURX is 3.06 USD with a low forecast of 3.03 USD and a high forecast of 3.15 USD.

AURX Lowest Forecast
Wall Street Target
3.03 USD
89% Upside
AURX Average Forecast
Wall Street Target
3.06 USD
91% Upside
AURX Highest Forecast
Wall Street Target
3.15 USD
97% Upside
Lowest
Price Target
3.03 USD
89% Upside
Average
Price Target
3.06 USD
91% Upside
Highest
Price Target
3.15 USD
97% Upside
Nuo Therapeutics Inc Competitors:
Price Targets
TES
Tesmec SpA
-11% Downside
BTBT
Bit Digital Inc
233% Upside
VLA
Valneva SE
53% Upside
V
VERK
Verkkokauppa.com Oyj
25% Upside
TES
Tesmec SpA
-11% Downside
BTBT
Bit Digital Inc
233% Upside
VLA
Valneva SE
53% Upside
V
VERK
Verkkokauppa.com Oyj
25% Upside

Revenue
Forecast

-12% / Year
Past Growth
79% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
-12% / Year
Past Growth
79% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 13 years the compound annual growth rate for Nuo Therapeutics Inc's revenue is -12%. The projected CAGR for the next 4 years is 79%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Operating Income forecast
is not available for
Nuo Therapeutics Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

What are analyst estimates?

See Also

Summary
AURX intrinsic value, competitors valuation, and company profile.
DCF Valuation
AURX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AURX stock valuation using valuation multiples.
Wall Street Estimates
AURX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AURX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AURX's stock price target?
Price Target
3.06 USD

According to Wall Street analysts, the average 1-year price target for AURX is 3.06 USD with a low forecast of 3.03 USD and a high forecast of 3.15 USD.

What is Nuo Therapeutics Inc's Revenue forecast?
Projected CAGR
79%

For the last 13 years the compound annual growth rate for Nuo Therapeutics Inc's revenue is -12%. The projected CAGR for the next 4 years is 79%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 319,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.